Comparative Pharmacology
Head-to-head clinical analysis: ESKALITH versus ESKALITH CR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ESKALITH versus ESKALITH CR.
ESKALITH vs ESKALITH CR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lithium modulates neurotransmission by inhibiting inositol monophosphatase, leading to reduced phosphoinositide signaling; also inhibits glycogen synthase kinase-3 (GSK-3) and alters neuronal excitability via effects on sodium transport and neurotransmitter release.
Lithium modulates neurotransmitter activity, inhibits inositol monophosphatase, affects G-protein signaling, and alters gene expression for neuroprotective effects.
Lithium carbonate extended-release: 300-600 mg orally twice daily, titrated to serum levels 0.6-1.2 mEq/L. Immediate-release: 300-600 mg three times daily.
Lithium carbonate extended-release (Eskalith CR) is administered orally. Typical adult starting dose: 300 mg 2-3 times daily. Maintenance dose: 900-1200 mg/day in 2-3 divided doses. Dose adjustments guided by serum lithium levels (target 0.6-1.2 mEq/L). Maximum dose: 2400 mg/day.
None Documented
None Documented
Terminal elimination half-life: 18-24 hours (range 12-27 hours) in adults; may be prolonged in elderly or renal impairment. Steady-state achieved in 5-7 days.
Terminal half-life: 18–24 hours (single dose); 24–36 hours (steady state). Extended due to slow tissue redistribution and age-related decreased GFR.
Renal: >95% excreted unchanged in urine. Biliary/fecal: negligible (<1%).
Renal: >95% unchanged. Biliary/fecal: negligible (<1%).
Category C
Category C
Mood Stabilizer
Mood Stabilizer